Loss of Rb2/p130 expression have been reported to be an important parameter for risk assessment of various cancers including non-small cell lung cancer progression [39, 40], endometrial and mammary carcinomas [37], ovarian cancers [15, 16] in their initial stages. The gene discussed is RBL2; the disease is ovarian cancer.